Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning

[1]  E. Krenning,et al.  Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors , 2018, The Journal of Nuclear Medicine.

[2]  M. Cremonesi,et al.  Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive? , 2017, The Journal of Nuclear Medicine.

[3]  M. Ferrari,et al.  Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. , 2017, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[4]  E. Krenning,et al.  Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors , 2017, Clinical Cancer Research.

[5]  Jean-Mathieu Beauregard,et al.  Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Michael Ljungberg,et al.  Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  C. Strassburg,et al.  Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[9]  J. Beauregard,et al.  Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: a simulation study , 2016 .

[10]  P. Bernhardt,et al.  A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity , 2016, EJNMMI Physics.

[11]  P. Bernhardt,et al.  Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume , 2016, EJNMMI Physics.

[12]  E. Krenning,et al.  Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  E. Krenning,et al.  Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. , 2016, Seminars in nuclear medicine.

[14]  P. Fenaux,et al.  High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. , 2016, Endocrine-related cancer.

[15]  E. Krenning,et al.  Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Anders Sundin,et al.  Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE , 2015, The Journal of Nuclear Medicine.

[17]  Michael Lassmann,et al.  The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  M. Kesavan,et al.  Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up , 2014, Neuroendocrinology.

[19]  I. Drozdov,et al.  Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  F. Mottaghy,et al.  Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  H. Biersack,et al.  Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  C. Rochlitz,et al.  Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  G. Ventroni,et al.  Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  H. Biersack,et al.  Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate , 2013, The Journal of Nuclear Medicine.

[25]  M. Iori,et al.  Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors , 2013, BioMed research international.

[26]  C. Bal,et al.  Dosimetric Analyses of Kidneys, Liver, Spleen, Pituitary Gland, and Neuroendocrine Tumors of Patients Treated With 177Lu-DOTATATE , 2013, Clinical nuclear medicine.

[27]  M. Lubberink,et al.  Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment , 2013, The Journal of Nuclear Medicine.

[28]  V. Prasad,et al.  Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose? , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[29]  A. Kangasmäki,et al.  4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[30]  C. Rochlitz,et al.  Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study , 2013, Journal of Translational Medicine.

[31]  G. Lomuscio,et al.  Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy). , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[32]  Santosh Gupta,et al.  Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. , 2012, Cancer biotherapy & radiopharmaceuticals.

[33]  Eva Forssell-Aronsson,et al.  Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy , 2012, EJNMMI Research.

[34]  A. Versari,et al.  Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience , 2012, Journal of oncology.

[35]  M. Ferrari,et al.  Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  Matthias Briel,et al.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Gregersen,et al.  Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland , 2011, Neuroendocrinology.

[38]  Raffaella Barone,et al.  Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  J. Turner,et al.  Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  J. Walecki,et al.  Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Marion de Jong,et al.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. , 2010, Endocrine-related cancer.

[42]  X Allen Li,et al.  Radiation-associated kidney injury. , 2010, International journal of radiation oncology, biology, physics.

[43]  E. Yorke,et al.  Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.

[44]  Michael Ljungberg,et al.  177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy , 2010, Cancer.

[45]  C. Bodet-Milin,et al.  Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy , 2010, Cancer.

[46]  A Rossi,et al.  Dosimetry for treatment with radiolabelled somatostatin analogues. A review. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[47]  Anders Sundin,et al.  Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  Eva Forssell-Aronsson,et al.  [177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney , 2010, World Journal of Surgery.

[49]  Marion de Jong,et al.  Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[50]  George Sgouros,et al.  MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide Therapy* , 2008, Journal of Nuclear Medicine.

[51]  Giovanni Paganelli,et al.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[52]  R. Vetter.  ICRP Publication 103, The Recommendations of the International Commission on Radiological Protection , 2008 .

[53]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Richard P Baum,et al.  Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. , 2007, Cancer biotherapy & radiopharmaceuticals.

[55]  Glenn D. Flux,et al.  Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors , 2007 .

[56]  Adrian K. Dixon,et al.  Benefits and costs, an eternal balance , 2007 .

[57]  C. Hindorf,et al.  Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. , 2007, Cancer biotherapy & radiopharmaceuticals.

[58]  Marion de Jong,et al.  Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  J. Valentin.  The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. , 2007, Annals of the ICRP.

[60]  Giampiero Tosi,et al.  Dosimetry in Peptide radionuclide receptor therapy: a review. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  E. P. Krenning,et al.  Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[62]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  Raffaella Barone,et al.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  Raffaella Barone,et al.  Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  M. Cremonesi,et al.  A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[67]  P. Bartenstein,et al.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[68]  M. Cremonesi,et al.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[69]  L. Kvols,et al.  86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[70]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[71]  H. Herzog,et al.  Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide , 2001, European Journal of Nuclear Medicine.

[72]  S. Weiner,et al.  End-stage renal disease after treatment with 90Y-DOTATOC , 2001, European Journal of Nuclear Medicine.

[73]  E. Krenning,et al.  [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients , 2001, European Journal of Nuclear Medicine.

[74]  E P Krenning,et al.  [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. , 2001, European journal of nuclear medicine.

[75]  F. Orsi,et al.  Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC , 1999, European Journal of Nuclear Medicine.

[76]  E. Krenning,et al.  Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  R G Dale,et al.  Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.

[78]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[79]  R. Sievert,et al.  Book Reviews : Recommendations of the International Commission on Radiological Protection (as amended 1959 and revised 1962). I.C.R.P. Publication 6. 70 pp. PERGAMON PRESS. Oxford, London and New York, 1964. £1 5s. 0d. [TB/54] , 1964 .